Micromet to Present at the 16th Annual NewsMakers in the Biotech Industry Conference on September 16, 2009
September 15 2009 - 2:04PM
PR Newswire (US)
BETHESDA, Md., Sept. 15 /PRNewswire-FirstCall/ -- Micromet, Inc.
(NASDAQ: MITI), a biopharmaceutical company developing novel,
proprietary antibodies for the treatment of cancer, inflammation
and autoimmune diseases, today announced that its President and
CEO, Dr. Christian Itin, will present at the 16th Annual NewsMakers
in the Biotech Industry Conference on September 16, 2009 in New
York City, at the Millennium Broadway Hotel. A simultaneous webcast
of the event will be available on the company's website at
http://www.micromet-inc.com/. Forum: 16th Annual NewsMakers in the
Biotech Industry Conference Date: Wednesday, September 16, 2009
Time: 11:00 am to 11:25 am U.S. Eastern Daylight Savings Time
Place: Millennium Broadway Hotel New York City, New York Webcast:
http://www.micromet-inc.com/ About Micromet, Inc. Micromet, Inc. is
a biopharmaceutical company developing novel, proprietary
antibodies for the treatment of cancer, inflammation and autoimmune
diseases. Its product development pipeline includes novel
antibodies generated with its proprietary BiTE antibody platform,
as well as conventional monoclonal antibodies. Two of Micromet's
BiTE antibodies and three of its conventional antibodies are
currently in clinical trials. Micromet's preclinical product
pipeline includes several novel BiTE antibodies generated with its
proprietary BiTE antibody platform technology. Micromet's
collaboration partners include Bayer Schering Pharma, Merck Serono,
MedImmune and Nycomed. Forward-Looking Statements This release
contains certain forward-looking statements that involve risks and
uncertainties that could cause actual results to be materially
different from historical results or from any future results
expressed or implied by such forward-looking statements. These
forward-looking statements include statements regarding the
efficacy, safety and intended utilization of blinatumomab and other
product candidates, the conduct, timing and results of future
clinical trials, and expectations of the future expansion of our
product pipeline and collaborations. You are urged to consider
statements that include the words "ongoing," "may," "will,"
"believes," "potential," "expects," "plans," "anticipates,"
"intends," or the negative of those words or other similar words to
be uncertain and forward-looking. Factors that may cause actual
results to differ materially from any future results expressed or
implied by any forward-looking statements include the risk that
product candidates that appeared promising in early research,
preclinical studies or clinical trials do not demonstrate safety
and/or efficacy in subsequent clinical trials, the risk that
encouraging results from early research, preclinical studies or
clinical trials may not be confirmed upon further analysis of the
detailed results of such research, preclinical study or clinical
trial, the risk that additional information relating to the safety,
efficacy or tolerability of our product candidates may be
discovered upon further analysis of preclinical or clinical trial
data, the risk that we or our collaborators will not obtain
approval to market our product candidates, the risks associated
with reliance on outside financing to meet capital requirements,
and the risks associated with reliance on collaborators, including
MedImmune, Merck Serono, TRACON and Nycomed, for the funding or
conduct of further development and commercialization activities
relating to our product candidates. These factors and others are
more fully discussed in Micromet's Quarterly Report on Form 10-Q
for the fiscal quarter ended June 30, 2009, filed with the SEC on
August 6, 2009, as well as other filings by the company with the
SEC. DATASOURCE: Micromet, Inc. CONTACT: US Media: Andrea tenBroek
or Chris Stamm, both at +1-781-684-0770, ; or US Investors: Susan
Noonan, +1-212-966-3650, ; or European Media: Ludger Wess,
+49(40)8816-5964, ; or European Investors: Ines-Regina Buth,
+49(30)2363-2768, Web Site: http://www.micromet-inc.com/
Copyright